⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5304361 | 0.83 | — | — | |
| SCHEMBL3354520 | 0.69 | CYP11B1 (0.41) | — | |
| SCHEMBL26613482 | 0.69 | — | — | |
| SCHEMBL965068 | 0.64 | — | — | |
| SCHEMBL104616 | 0.64 | — | — | |
| SCHEMBL3782429 | 0.64 | — | — | |
| SCHEMBL16416850 | 0.62 | — | — | |
| SCHEMBL852319 | 0.62 | ALOX5 (0.46) | — | |
| SCHEMBL75634 | 0.62 | MMP12 (0.47) | — | |
| SCHEMBL9195443 | 0.62 | KDM4E (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113292539-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2023-12-22 | — | — | CN | disclosed |
| US-20230024752-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2023-01-26 | — | — | US | disclosed |
| US-11180471-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2021-11-23 | — | — | US | disclosed |
| CN-113292539-A | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-24 | — | — | CN | disclosed |
| CN-108026072-B | Substituted oxopyridine derivatives | 拜耳制药股份公司 | 2021-08-17 | — | — | CN | disclosed |
| CN-108164513-B | Substituted oxopyridine derivatives and their use in the treatment of cardiovascular disorders | 拜耳制药股份公司 | 2021-05-07 | — | — | CN | disclosed |
| EP-3319956-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES | Bayer Pharma AG (DE) | 2021-01-06 | — | — | EP | disclosed |
| US-10421742-B2 | Substituted oxopyridine derivatives | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-09-24 | — | — | US | disclosed |
| EP-2978756-B1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CARDIOVASCULAR DISEASES | Bayer Pharma AG (DE) | 2019-03-27 | — | — | EP | disclosed |
| US-10183932-B2 | Substituted oxopyridine derivatives and use thereof cardiovascular disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2019-01-22 | — | — | US | disclosed |
| US-20160152613-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-06-02 | — | — | US | disclosed |
| EP-3024822-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | Bayer Pharma Aktiengesellschaft (DE) | 2016-06-01 | — | — | EP | disclosed |
| WO-2016046157-A1 | FACTOR XIA-INHIBITING PYRIDOBENZAZEPINE AND PYRIDOBENZAZOCINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-03-31 | — | — | WO | disclosed |
| US-20160052884-A1 | Substituted Oxopyridine Derivatives and Use Thereof in the Treatment of Cardiovascular Disorders | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2016-02-25 | — | — | US | disclosed |
| EP-2978756-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | Bayer Pharma Aktiengesellschaft (DE) | 2016-02-03 | — | — | EP | disclosed |
| WO-2015044170-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES AND USE THEREOF TO TREAT THROMBOTIC/THROMBOEMBOLIC DISEASES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015044165-A1 | SUBSTITUTED PHENYLALANINE DERIVATIVES | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-04-02 | — | — | WO | disclosed |
| WO-2015011087-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF AS FACTOR XIA/PLASMA | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-01-29 | — | — | WO | disclosed |
| WO-2014154794-A1 | SUBSTITUTED OXOPYRIDINE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF CARDIOVASCULAR DISORDERS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2014-10-02 | — | — | WO | disclosed |
| WO-2007039170-A1 | ANTAGONISTS OF TOPOISOMERASE ACTIVITY AND THEIR USE IN INHIBITING PATHOLOGICAL CONDITIONS | EUROPEAN MOLECULAR BIOLOGY LABORATORY (EMBL) (DE) | 2007-04-12 | — | — | WO | disclosed |